AbbVie Inc.

01/14/2020 | Press release | Distributed by Public on 01/14/2020 07:54

New Head-to-Head Phase 3 Data Show SKYRIZI™ (risankizumab) Superior to Cosentyx® (secukinumab) Across Primary and All Ranked Secondary Endpoints in Adults with Moderate to[...]